Physician profile
Lore Vonhoffen
NPI 1407014525
$1,611.69
in general payments reported to CMS, 2019-2025
14 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $836 · 2022: $223 · 2023: $165 · 2024: $201 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $327.85 | 2021-2025 | Caldolor |
| Astrazeneca Pharmaceuticals LP | $246.57 | 2021 | |
| Janssen Pharmaceuticals, INC | $225.09 | 2021-2024 | Xarelto |
| Chiesi USA, INC. | $153.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $125.13 | 2025 | Zerbaxa |
| Genentech USA, INC. | $119.34 | 2021 | |
| Gilead Sciences, INC. | $103.26 | 2024 | Veklury |
| Kci USA, INC. | $57.68 | 2021-2023 | V.A.C. Dermatac, Prevena Restor Bellaform, V.A.C. Veraflo |
| Solventum Corporation | $56.00 | 2024-2025 | Prevena, V.A.C. Dermatac, V.A.C. Veraflo Cleanse Choice |
| Becton, Dickinson and Company | $54.37 | 2022 | |
| Shionogi INC | $50.67 | 2021-2023 | Fetroja |
| Melinta Therapeutics, LLC | $39.24 | 2024-2025 | Rezzayo, Orbactiv, Kimyrsa |
| E.R. Squibb & Sons, L.L.C. | $39.00 | 2021-2022 | |
| Abbvie INC. | $14.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lore Vonhoffen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.